Gotowa bibliografia na temat „Rejet d’allogreffe”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Spis treści
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Rejet d’allogreffe”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "Rejet d’allogreffe"
Guilbert, E., L. Laroche i V. Borderie. "Le rejet d’allogreffe de cornée". Journal Français d'Ophtalmologie 34, nr 5 (maj 2011): 331–48. http://dx.doi.org/10.1016/j.jfo.2011.02.001.
Pełny tekst źródłaClaustre, J., C. Trocmé, S. Bourgoin-Voillard, H. Flamant-Waret, I. Bérard, B. Toussaint, K. Botturi-Cavaillès i in. "Recherche de biomarqueurs prédictifs de rejet chronique d’allogreffe pulmonaire par analyses protéomiques". Revue des Maladies Respiratoires 32 (styczeń 2015): A250. http://dx.doi.org/10.1016/j.rmr.2014.10.708.
Pełny tekst źródłaPonchel, C., J. L. Arné, F. Malecaze i P. Fournié. "Rejet d’allogreffe de cornée après Descemet stripping automated endothelial keratoplasty (DSAEK) : à propos de trois cas". Journal Français d'Ophtalmologie 32, nr 4 (kwiecień 2009): 257–62. http://dx.doi.org/10.1016/j.jfo.2009.02.002.
Pełny tekst źródłaRabant, Marion, Julien Calvani, Megumi Terada, Corinne Lesaffre, Jean-Paul Duong Van Huyen i Patrick Bruneval. "Immunofluorescence multiparamétrique in situ : vers l’amélioration du phénotype de l’infiltrat cellulaire au cours du rejet d’allogreffe rénale". Néphrologie & Thérapeutique 15 (kwiecień 2019): S43—S52. http://dx.doi.org/10.1016/j.nephro.2019.03.008.
Pełny tekst źródłaTinel, C., G. Dautin, L. Martin, M. Funes de la Vega i C. Mousson. "Faut-il rechercher les anticorps anti-HLA fixant le C1q au cours du rejet chronique d’allogreffe rénale à médiation humorale ?" Néphrologie & Thérapeutique 8, nr 5 (wrzesień 2012): 275–76. http://dx.doi.org/10.1016/j.nephro.2012.07.321.
Pełny tekst źródłaCalvani, Julien, Megumi Terada, Corinne Lesaffre, Jean-Paul Duong Van Huyen, Patrick Bruneval i Marion Rabant. "Erratum à « Immunofluorescence multiparamétrique in situ : vers l’amélioration du phénotype de l’infiltrat cellulaire au cours du rejet d’allogreffe rénale » [Nephrol. Ther. 15S (2019) S43–S52]". Néphrologie & Thérapeutique 15, nr 7 (grudzień 2019): 553. http://dx.doi.org/10.1016/j.nephro.2019.11.001.
Pełny tekst źródłaTouzot, M., G. Couvrat-Desvergnes, S. Castagnet, A. Cesbron, K. Renaudin i M. Giral. "Effets contrastés des thérapies B-déplétantes sur les anticorps anti-HLA spécifiques du donneur chez des receveurs d’allogreffe rénale traités pour des rejets humoraux chroniques actifs". Néphrologie & Thérapeutique 9, nr 5 (wrzesień 2013): 270. http://dx.doi.org/10.1016/j.nephro.2013.07.165.
Pełny tekst źródłaChaudhari, Ishan, Marianna Leung i Bita Bateni. "Characterization of Cytomegalovirus Viremia in Renal Transplant Recipients". Canadian Journal of Hospital Pharmacy 75, nr 1 (8.01.2022). http://dx.doi.org/10.4212/cjhp.v75i1.3249.
Pełny tekst źródłaRozprawy doktorskie na temat "Rejet d’allogreffe"
Bonnet, Guillaume. "Stratification du risque cardio-vasculaire et de mortalité chez le patient transplanté cardiaque". Electronic Thesis or Diss., Université Paris Cité, 2021. http://www.theses.fr/2021UNIP5251.
Pełny tekst źródłaMore than 5000 heart transplants are performed each year worldwide, with a median post-transplant survival of more than 12 years. Risk stratification of post-transplant outcomes has become a priority for the transplant community, particularly in the face of the new French allocation system and following the recent revision of the US cardiac allocation system. The objective of this work was to identify ways to improve the risk stratification of cardiovascular events and mortality in heart transplant patients. First, in our analysis of a contemporary United Network for Organ Sharing (UNOS) cohort, we showed that circulatory support status at the time of transplantation was associated with large differences in patient characteristics and prognosis, and influenced post-transplant predictive models. However, the development of specific predictive models for each type of circulatory support had a limited impact on the statistical performance of the predictive models. Beyond the limitations that these approaches may represent on large national databases (low level of granularity with the absence of immunological data, missing data in the follow-up), we have constituted a multicentric and highly phenotyped prospective Ile-de-France database of heart transplant patients. Within this specific population and following a detailed medical review of the causes of death, our results showed that sudden death was a large cause of death beyond the first year post-transplant. We demonstrated that the annual incidence of sudden death was 25 times higher than in the general population. The risk of sudden death was significantly higher in younger recipients. Five variables were independently associated with sudden death: older donor age, younger recipient age, ethnicity, pre-existing donor-specific antibodies and left ventricular ejection fraction. Our results provide new insights into the epidemiology of sudden death after heart transplantation. Finally, we identified, for the first time, 4 distinct trajectories of long-term progression of cardiac allograft vasculopathy using an innovative unsupervised approach. These 4 trajectories were consistent and validated in geographically distinct cohorts (Europe and USA). We found that these trajectories were associated with specific donor and recipient characteristics, ongoing disease processes including rejection, and early immunological profiles after transplantation. Thus, patient trajectory assessment that can be performed at an early stage after transplantation can optimise post-transplant risk stratification. These different avenues can lead to the development of new risk stratification tools, which can sometimes be transposed to daily practice. The identification of subgroups of high-risk patients would lead to more aggressive preventive strategies to improve overall long-term survival